A number of studies indicate that the female gonadal hormone, estrogen, confers protection against stroke. For example, during middle cerebral artery occlusion (MCAO), a model for stroke, untreated female rats sustain approximately one third of the total tissue infarction observed in males or ovariectomized females. 1 Treatment of male rats with estrogen protects male brains during MCAO, reducing infarct volume by similar amounts. 2 Structural and functional consequences of common carotid artery thrombosis are worsened by endothelial nitric oxide synthase (eNOS) inhibition, indicating that eNOS protects against brain injury. 3 Action of estrogen on the enzyme eNOS may contribute to the protective effects of this hormone. We recently demonstrated that estrogen treatment increases nitric oxide synthase (NOS)-mediated modulation of cerebrovascular reactivity in gonadectomized female 4 and male 5 rats. Cerebral microvessels contribute a considerable portion of the total resistance to blood flow and are important in the coupling of brain metabolism to regional blood flow. 6 Therefore, we investigated the hypothesis that estrogen upregulates expression of eNOS in cerebral microvessels by measuring levels of eNOS protein in animals of differing hormonal status.
See Editorial Comment, page 2190

Materials and Methods
Animal Treatment
Seven groups of rats were compared: females, ovariectomized females, ovariectomized females treated with estrogen, males, castrated males, castrated males treated with estrogen, and castrated males treated with testosterone. Gonadectomies were performed on 3-month-old Fischer 344 rats (Harlan Sprague-Dawley) anesthetized with ketamine 90 mg/kg and xylazine 10 mg/kg IP. In some animals, hormone treatment (estrogen or testosterone) was started at the time of gonadectomy by implanting hormone-filled silicone elastomer capsules subcutaneously. 7 The capsules remained in place until the animal was killed. Animals were killed by decapitation 4 weeks after gonadectomy, and brains were immediately frozen at Ϫ20°C. Serum levels of estradiol were determined with the use of a double-antibody 125 I radioimmunoassay kit (Diagnostic Products) as previously described. 4 Serum levels of testosterone were determined with the use of a doubleantibody 125 I radioimmunoassay kit (ICN Biochemicals).
Microvessel Isolation
Cerebral microvessels were isolated from rat brain parenchyma by methods described previously. 8, 9 Briefly, 4 brains were pooled, homogenized gently with a Dounce tissue grinder in ice-cold PBS (0.01 mol/L, pH 7.4), and centrifuged (with the use of a Beckman GS15R swinging bucket rotor) at 2000g for 10 minutes at 4°C. The supernatant was then discarded, and the pellet was washed by resuspension in PBS and recentrifuged at 2000g for 10 minutes. The supernatant was discarded; the pellet was resuspended in PBS, gently layered on top of a dextran solution (15%; molecular weight, 38 400), and centrifuged at 3500g for 55 minutes. The pellet was then collected, resuspended in PBS, layered over dextran, and centrifuged at 4000g for 20 minutes. The final pellet was poured over a nylon mesh screen (50 m) and washed extensively with a strong stream of cold PBS. The microvessel fraction, containing small arterioles, venules, and capillaries, was collected from the top of the screen and stored at Ϫ20°C.
Lysis and Protein Content Determination
Microvessel samples were glass homogenized in a lysis buffer consisting of 50 mmol/L ␤-glycerophosphate, 
SDS-PAGE/Western Blot
For each animal group, 20 g of microvessel protein was loaded onto 8% Tris-glycine gels and separated by SDS-PAGE. Endothelial cell lysate and biotinylated broad-range molecular weight markers (Bio-Rad) were loaded onto the gels as well. After electrophoretic separation, proteins were transferred to a nitrocellulose membrane by electroblotting, and membranes were incubated overnight at 4°C in blocking buffer (PBS containing 1% Tween-20 [T-PBS] and 6.5% nonfat dry milk). Membranes were then incubated for 4 hours at room temperature with either a monoclonal mouse antieNOS, anti-iNOS, or anti-nNOS antibody (Transduction Laboratories, 1:500 dilution in blocking buffer), rinsed with T-PBS for 30 minutes, and incubated with anti-mouse IgG antibody conjugated to horseradish peroxidase (Transduction Laboratories, 1:10 000 dilution in blocking buffer). Membranes were rinsed with T-PBS for 30 minutes, incubated with electrochemiluminescence reagent (Amersham) for 2 minutes, and apposed to hyperfilm (Amersham).
Data Analysis and Statistics
Densitometric analyses were performed with a computerbased image analysis system (MCID). In each of 4 separate experiments, microvessels from all 7 treatment groups were isolated and analyzed in parallel. In addition, measurements were made in duplicate in 3 of the 4 experiments. Data are expressed as meanϮSE. Statistical significance of Western blot and radioimmunoassay data was determined by ANOVA with the Prism software package, with repeated measures used for the Western blot data. Post hoc analysis was performed with Bonferroni's multiple comparison test (Prism software package), with comparisons made as follows: females versus males; ovariectomized females treated with estrogen and females versus ovariectomized females; and males, castrated males treated with estrogen, and castrated males treated with testosterone versus castrated males. Acceptable level of significance was defined as PϽ0.05.
Results
As indicated in the creased serum testosterone levels (PϽ0.001) but not serum estrogen levels. Females had significantly lower body weights than males (PϽ0.001), and surgery and/or hormone treatment had no significant effect on body weight in males or females. Uterine weight was significantly higher in females and ovariectomized females treated with estrogen compared with ovariectomized females (both PϽ0.001).
Immunoreactivity for eNOS was detected as a 140-kDa band in all microvessel preparations studied. Only 1 band was observed, and it corresponded to that of the positive control (cultured endothelial cells). Omission of the eNOS primary antibody or use of a negative control tissue (macrophages) resulted in omission of the band of interest (data not shown). No iNOS or nNOS immunoreactivity was detected in the isolated microvessels, although bands were detected for each of the positive controls (macrophages or brain homogenate, respectively; data not shown).
In females, estrogen treatment of ovariectomized animals resulted in a 17.4-fold increase in eNOS protein in cerebral microvessels, while intact females had 16.6-fold higher protein levels than ovariectomized females (both PϽ0.01; Figures 1A and 2A) . In intact females, eNOS protein levels in cerebral microvessels were 9.2-fold higher than those of intact males (PϽ0.05; Figure 1A) .
In males, neither castration nor testosterone treatment of castrated males altered levels of cerebral microvessel eNOS protein. Estrogen treatment of castrated animals resulted in an 18.8-fold increase in eNOS protein in cerebral microvessels (PϽ0.05; Figures 1B and 2B) .
Discussion
This study demonstrates 4 important findings. First, estrogen treatment increases the amount of eNOS protein in cerebral microvessels of both male and female gonadectomized rats. Second, neither castration of intact males nor testosterone treatment in castrated male rats alters the amount of eNOS protein. Third, ovariectomized female rats have less eNOS protein than intact females. Finally, intact female rats have greater levels of eNOS protein than intact males. These findings clearly demonstrate that exogenous or endogenous estrogen, but not testosterone, increases levels of eNOS protein in cerebral microvessels.
While exogenous or endogenous estrogen may have many sites of action in the animal, a direct effect on microvessel eNOS expression is likely. Genomic effects of chronic estrogen treatment on eNOS have been shown in other systems. Ovine pulmonary artery endothelial cells incubated with estrogen in culture show an increase in NOS activity as well as increases in eNOS mRNA and protein levels, and these effects are inhibited by treatment with ICI 182780, an estrogen receptor antagonist. 10 In cultured human endothelial cells, estrogen increases eNOS mRNA and protein via a receptor-mediated system, without affecting eNOS mRNA stability, and enhances binding of transcription factor Sp1, which is essential for the activity of the human eNOS promoter. 11, 12 In the rat aorta, eNOS mRNA increases with pregnancy or estrogen treatment but not with progesterone or testosterone treatment. 13 Therefore, it is likely that chronic estrogen treatment specifically increases both transcription and translation of eNOS, resulting in higher levels of eNOS protein throughout the vascular endothelium. How these findings might relate to protection from stroke is not completely clear. Chronic estrogen treatment results in improved stroke outcome after vascular occlusion in both male and female rats. 1,2 Some of the actions of estrogen that might contribute include the following: increased availability of vasodilatory molecules (such as NO), increased angiogenesis, functional differences in vascular reactivity, or antioxidant activity. 1 After MCAO, female rats have a smaller infarct size in both cerebral cortex and caudoputamen compared with males and ovariectomized females. Furthermore, during MCAO, female rats have higher laser-Doppler flow in the cerebral cortex and caudoputamen compared with male and ovariectomized female rats, suggesting that a flowpreserving effect of estrogen mediates neuroprotection in these areas. However, end-ischemic cerebral blood flow is greater in females than in males and ovariectomized females only in the caudoputamen (not in the cerebral cortex). Furthermore, when areas with similar levels of very low cerebral blood flow are compared, intact females sustain smaller infarction volumes than do ovariectomized females. 1 This implies that estrogen may improve stroke outcome by more than 1 mechanism, exerting both flow-preserving as well as other neuroprotective effects.
Whether the flow-preserving effect of estrogen during ischemia is mediated via increased eNOS activity is not known. In nonischemic conditions, there are no differences in laser-Doppler flow rates in the caudoputamen or cerebral cortex when female, male, and ovariectomized female rats are compared. 1 However, in parallel to this study, our laboratory has shown that estrogen reduces myogenic tone in rat middle cerebral arteries through an N G -nitro-L-arginine methyl ester (L-NAME)-sensitive mechanism, suggesting that NO production and/or sensitivity is greater when estrogen is present. 4, 5 Because the results from the present study suggest that more eNOS protein is present in the cerebral circulation of estrogen-treated animals, it is likely that this functional effect of estrogen treatment is mediated by greater NO production in response to myogenic tone. While increased levels of eNOS may not affect resting blood flow, the capacity of females to respond to conditions of altered flow or perfusion pressure may be enhanced by estrogen treatment.
A number of studies in both male and female humans suggest that chronic estrogen exposure increases the capacity of the endothelium to produce NO in response to changes in flow. For example, estrogen replacement in postmenopausal women both decreases blood pressure 14 and increases the flow-induced, endothelium-dependent vasodilation in the brachial artery as measured by ultrasonography. 15 In premenopausal women, increased flow-induced, endotheliumdependent vasodilation in peripheral blood vessels has been shown to parallel levels of serum estrogen and NO metabolites during the normal menstrual cycle. 16, 17 Furthermore, endothelium-dependent, flow-induced vasodilation has been shown to be absent in a man with a disruptive mutation in the estrogen receptor gene. 18 Paired with the results of the present study, one explanation for these data is that chronic estrogen treatment increases flow-induced vasodilation in males and premenopausal and postmenopausal females through an increase in eNOS protein, increasing the capacity of the endothelium to release NO.
In addition to these chronic effects of estrogen that appear to involve classic genomic estrogen receptor effects, it should be noted that there is also an acute effect of estrogen to increase NO production independent of protein synthesis. 19 -21 These studies raise important questions regarding the hormonal regulation of eNOS, including the possible dual effects of estrogen: both an acute effect on eNOS activity and a chronic effect on eNOS protein levels.
Acute effects of estrogen have been investigated in relation to stroke, but different studies have found different effects of acute estrogen pretreatment immediately before induction of ischemia. In males, acute estrogen treatment results in a decrease in infarction volume, 2 while in ovariectomized females, acute estrogen treatment had no effect on infarction volume. 22 In both cases, acute estrogen had no effect on cerebral blood flow during ischemia, indicating that other, eNOS-independent, neuroprotective effects of estrogen may mediate the acute effect found in males.
Other effects of chronic estrogen treatment on the cerebral circulation have been previously shown. For example, cGMP is elevated in microvascular blood vessels isolated from female rabbits treated chronically with high doses of estrogen. 23 Paired with the data from the present study, it is likely that this increase in cGMP is secondary to an increase in levels of eNOS protein and NO production. In premenopausal women treated with leuprolide to induce ovarian suppression, chronic estrogen treatment increases regional cerebral blood flow during cognitive activation, as measured by positron emission tomography, 24 and increases plasma nitrates. 25 It is possible that an increased amount of eNOS protein after estrogen treatment allows for greater cerebral vasodilating capacity in response to a variety of stimuli.
In summary, many studies suggest that estrogen acts in males and premenopausal and postmenopausal females to increase levels of NO, which then mediate vasodilation. The present study indicates that this increase in NO production may be secondary to an effect of estrogen to increase levels of eNOS protein in both males and females. Together with our previous studies showing an NO-dependent effect of estrogen to modulate cerebral vascular reactivity, these studies support the hypothesis that an increase in eNOS protein due to estrogen treatment may contribute to the flowpreserving neuroprotective effects of estrogen.
Editorial Comment
It is well established that estrogen has a protective effect against stroke. The accompanying article by McNeill and colleagues sheds light on one of the mechanisms by which this effect is mediated. The authors showed that estrogen treatment caused increases in the amount of eNOS protein in cerebral microvessels in both male and female gonadectomized rats. They also found that ovariectomy in female rats caused a decrease in eNOS protein. In addition, female rats had greater amounts of eNOS protein than male rats. Testosterone did not appear to have any effect on cerebral eNOS concentration. It therefore appears likely that the protective effect of estrogen against stroke may be mediated for the most part through increased generation of eNOS, which results in increased production of NO and in vasodilation.
There is some evidence in the literature, as the authors point out, that suggests that this effect of estrogen may be also present in humans. Studies of this type may ultimately explain more fully the sex-related differences in the incidence of stroke and sex-related differences in the consequences of ischemia that have long puzzled physicians and scientists. 
